Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q2 2022 · 10-Q
Revenue$29.81M$29.81M+22.3% vs Q2 2021 Net Income-$72.62M-$72.62MN/M vs Q2 2021 EPS Diluted-$0.78-$0.78N/M vs Q2 2021 Operating Income-$78,224,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$33,969,000N/M Margins · derivedOperating margin-262.4%+286.9 pt vs Q2 2021
Net margin-243.7%+306.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 8, 2022 · 39 d after period end